EVFM 53X Upside potential according to Morgan Stanley !

EVFM Evofem Biosciences has a big upcoming catalyst:
Its Phase 3 clinical trial evaluating Phexxi for the prevention of chlamydia and gonorrhea in women is on track to report top-line data from this landmark trial in mid-October, so we are one week away from results!
Positive study outcomes would enable potential U.S. approval for prevention of these sexually transmitted infections in 2023.
Evofem`s Phexxi whas already approved in Nigeria, the most populous country in Africa and the seventh largest country in the world, 3 days ago.

On 4/12/2022 Jeffrey Hung from Morgan Stanley Boosted the Price Target for EVFM to Underweight, from $7.95 to $8.55.
On 8/15/2022 HC Wainwright Boosted the Price Target to $4.00, giving a Buy Rating.

Now the stock is trading at all time low, $0.16, while 4 months ago it was trading 10X higher.

In my opinion this is a premium call and a great buy opportunity ahead of a Big upcoming catalyst for EVFM Evofem Biosciences.

Looking forward to read your opinion about it.